DUARTE, Calif. (May 19, 2023) – Prolacta Bioscience, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, celebrates World Human Milk Donation Day May 19 by recognizing the donor moms who make an Exclusive Human Milk Diet (EHMD) possible for vulnerable infants in hospitals around the world.
Prolacta’s fortifiers are made from 100% human milk donated from moms who produce excess breast milk and want to make a difference in the lives of critically ill, premature infants. Prolacta’s donors nurture their own infants and nourish others through their donations. Since 2007, over 20,000 donor moms have provided more than 1.7 million liters of breast milk to help give brighter futures to more than 90,000 babies throughout the world.1
“Being a breast milk donor isn’t easy. It takes significant time and effort to donate excess breast milk and meet the stringent safety standards required to help medically fragile infants,” said Susan Neumann, vice president of milk resourcing at Prolacta. “We are proud to offer our donors the option of compensation to recognize their dedication and hard work. Without our donor moms, critically ill infants would not have access to the essential human milk-based nutrition they need to grow and thrive.”
Prolacta’s donors take care to ensure their milk meets Prolacta’s stringent quality and safety standards. Before their milk is used for Prolacta’s products, moms undergo a thorough qualification process, as well as health screenings and tests of their breast milk, due to the vulnerable infant population Prolacta serves. Once qualified, donor moms spend hours per day on activities required to donate their excess breast milk, including pumping, cleaning and sanitizing pump parts, storing and freezing, packing and shipping, and staying hydrated and nourished.
“We are incredibly grateful to our donor moms for their dedication and generosity in providing human milk to infants in need, and their passion to adhere to stringent safety measures to keep their own infants and the vulnerable infants we serve safe and well-nourished,” said Scott Elster, CEO of Prolacta. “These moms ensure that premature infants receive the best possible nutrition during their critical first weeks of life, which can have a lasting impact on their health and development. We are honored to work with these amazing individuals to help improve the health outcomes of thousands of infants.”
Learn more about Prolacta’s “Human Milk Champions” and the positive impact these donor moms make on the lives of medically fragile infants.
About Prolacta Bioscience
Prolacta Bioscience® Inc. is a privately held, global life sciences company dedicated to Advancing the Science of Human Milk® to improve the health of critically ill, premature infants. Prolacta’s 100% human milk-based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals. More than 90,000 premature infants have benefited from Prolacta’s nutritional products worldwide to date.1 Established in 1999, Prolacta is the world’s leading provider of human milk-based nutritional products for hospital use and is also exploring the therapeutic potential of human milk across a wide spectrum of diseases. Prolacta maintains the industry’s strictest quality and safety standards for screening, testing, and processing donor human milk. Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta uses vat pasteurization and a patented, FDA-reviewed manufacturing process to ensure pathogen inactivation while protecting the nutritional composition and bioactivity of its human milk-based products. Prolacta is a global company with headquarters in Duarte, California, and can be found online at Twitter, Instagram, Facebook, and LinkedIn.
# # #